Leqembi: The $26K Alzheimer's Drug Uncovered by US Insurance - A Deep Dive
Channel: NewsBytesAI
Date: 2023-08-13

Welcome to our latest video where we delve into the controversial debate around the coverage of Leqembi, a groundbreaking drug developed to slow cognitive decline in Alzheimer's patients. Despite the hefty annual price tag of $26,000, it's a ray of hope in the darkness for many patients and their families. 

In the first part of our video, we'll explore how private insurers in states like North Carolina, Pennsylvania, and New York are denying coverage for Leqembi, deeming it as an 'experimental' drug. This is despite the fact that Leqembi has been fully approved and is the first of its kind to fight against the mental deterioration caused by Alzheimer's. We'll examine why these insurers are refusing to cover it under individual market or employer insurance, a stark contrast to Medicare's stance.

The second segment will spotlight Medicare, which has announced coverage for most patients who take Leqembi. We'll delve into the specifics of how this coverage came about, following the drug's full approval last month. Around 76 percent of the people taking Leqembi will be covered by Medicare, as per Japanese drugmaker Eisai and Biogen Incorporated, the companies co-marketing the drug. 

In the third part of the video, we'll discuss the outcry against the refusal of commercial plans to cover Leqembi, blatantly labeled as 'discrimination.' We’ll provide up-to-date information on the stance of several significant insurers towards Leqembi, including Kaiser Permanente and Elevance Health who have confirmed coverage, and UnitedHealthcare who declined to comment.

Finally, in our concluding segment, we'll throw light on the potential risks faced by patients who are waiting for coverage. We'll discuss how this waiting period is a gamble as patients may advance out of early-stage Alzheimer’s and no longer qualify for Leqembi. 

Stay tuned to our channel for this insightful coverage and join us in discussing the implications of this development. We aim to keep you informed and aware, and your support helps us in our mission. Don't forget to like, share, and subscribe to stay updated with the latest healthcare news.



#Privateinsurers #NorthCarolina #Pennsylvania #NewYork #Leqembi #Alzheimer's #Medicare #mentaldecline #experimentaldrug #healthinsurance #FDAapproved #milddementia #earlyAlzheimer'ssymptoms #Eisai #BiogenIncorporated #discrimination #commercialinsurance #KaiserPermanente #ElevanceHealth #UnitedHealthcare #MedicareAdvantage #drugcoverage #healthcarepolicy #cognitivedecline #Alzheimer'streatment #healthcarediscrimination #drugapproval #healthcarecontroversy #TaylorSwift